Centessa Pharmaceuticals (CNTA) Competitors $16.79 -0.21 (-1.24%) Closing price 08/26/2025 04:00 PM EasternExtended Trading$17.34 +0.55 (+3.28%) As of 08/26/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTA vs. VRNA, ELAN, BPMC, ROIV, GRFS, LEGN, RVMD, RYTM, RNA, and NUVLShould you be buying Centessa Pharmaceuticals stock or one of its competitors? The main competitors of Centessa Pharmaceuticals include Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Centessa Pharmaceuticals vs. Its Competitors Verona Pharma PLC American Depositary Share Elanco Animal Health Blueprint Medicines Roivant Sciences Grifols Legend Biotech Revolution Medicines Rhythm Pharmaceuticals Avidity Biosciences Nuvalent Centessa Pharmaceuticals (NASDAQ:CNTA) and Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations. Do institutionals and insiders believe in CNTA or VRNA? 82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.9% of Verona Pharma PLC American Depositary Share shares are owned by institutional investors. 7.1% of Centessa Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of Verona Pharma PLC American Depositary Share shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts prefer CNTA or VRNA? Centessa Pharmaceuticals currently has a consensus price target of $28.10, indicating a potential upside of 67.36%. Verona Pharma PLC American Depositary Share has a consensus price target of $109.00, indicating a potential upside of 3.15%. Given Centessa Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Centessa Pharmaceuticals is more favorable than Verona Pharma PLC American Depositary Share.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 3.00Verona Pharma PLC American Depositary Share 0 Sell rating(s) 12 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14 Which has preferable valuation & earnings, CNTA or VRNA? Verona Pharma PLC American Depositary Share has higher revenue and earnings than Centessa Pharmaceuticals. Verona Pharma PLC American Depositary Share is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentessa Pharmaceuticals$6.85M328.23-$235.76M-$1.79-9.38Verona Pharma PLC American Depositary Share$42.28M216.19-$173.42M-$0.99-106.74 Is CNTA or VRNA more profitable? Centessa Pharmaceuticals has a net margin of 0.00% compared to Verona Pharma PLC American Depositary Share's net margin of -36.62%. Verona Pharma PLC American Depositary Share's return on equity of -21.12% beat Centessa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Centessa PharmaceuticalsN/A -40.39% -29.87% Verona Pharma PLC American Depositary Share -36.62%-21.12%-9.07% Does the media refer more to CNTA or VRNA? In the previous week, Verona Pharma PLC American Depositary Share had 7 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 12 mentions for Verona Pharma PLC American Depositary Share and 5 mentions for Centessa Pharmaceuticals. Verona Pharma PLC American Depositary Share's average media sentiment score of 1.71 beat Centessa Pharmaceuticals' score of 0.61 indicating that Verona Pharma PLC American Depositary Share is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verona Pharma PLC American Depositary Share 10 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has more volatility & risk, CNTA or VRNA? Centessa Pharmaceuticals has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Verona Pharma PLC American Depositary Share has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500. SummaryCentessa Pharmaceuticals and Verona Pharma PLC American Depositary Share tied by winning 8 of the 16 factors compared between the two stocks. Get Centessa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTA vs. The Competition Export to ExcelMetricCentessa PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.28B$2.50B$5.72B$9.73BDividend YieldN/A1.67%3.95%4.04%P/E Ratio-9.3822.5330.2926.09Price / Sales328.23496.64381.2787.63Price / CashN/A178.3537.7259.08Price / Book6.516.4610.046.67Net Income-$235.76M$32.94M$3.27B$265.43M7 Day Performance-2.84%2.46%3.68%3.36%1 Month Performance8.96%1.01%3.85%0.39%1 Year Performance24.37%6.21%35.59%19.43% Centessa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTACentessa Pharmaceuticals2.2211 of 5 stars$16.79-1.2%$28.10+67.4%+20.6%$2.28B$6.85M-9.38200News CoverageVRNAVerona Pharma PLC American Depositary Share2.4806 of 5 stars$105.79+0.5%$109.00+3.0%+295.9%$8.96B$42.28M-106.8630Positive NewsELANElanco Animal Health2.847 of 5 stars$17.72-1.4%$17.33-2.2%+23.6%$8.92B$4.44B20.609,000BPMCBlueprint MedicinesN/A$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences3.1904 of 5 stars$11.81-0.3%$16.50+39.7%+0.5%$8.06B$29.05M-16.87860GRFSGrifols3.5827 of 5 stars$10.58-1.3%$10.30-2.6%+14.3%$7.37B$7.45B9.0423,822Positive NewsLEGNLegend Biotech3.897 of 5 stars$37.45-0.1%$72.38+93.3%-38.1%$6.89B$627.24M-42.562,609News CoveragePositive NewsAnalyst ForecastRVMDRevolution Medicines4.3933 of 5 stars$36.45+0.4%$69.54+90.8%-15.4%$6.79B$11.58M-8.10250Positive NewsRYTMRhythm Pharmaceuticals3.5234 of 5 stars$98.09+0.5%$101.57+3.5%+102.4%$6.48B$130.13M-32.59140Positive NewsInsider TradeRNAAvidity Biosciences2.9668 of 5 stars$44.48-4.3%$67.00+50.6%+6.5%$5.98B$10.90M-12.49190Positive NewsNUVLNuvalent3.374 of 5 stars$75.01-1.4%$119.60+59.4%-10.9%$5.48BN/A-15.3140News CoveragePositive News Related Companies and Tools Related Companies VRNA Alternatives ELAN Alternatives BPMC Alternatives ROIV Alternatives GRFS Alternatives LEGN Alternatives RVMD Alternatives RYTM Alternatives RNA Alternatives NUVL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTA) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Centessa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access